GSK has announced on Tuesday that it intends to appoint Deloitte LLP (“Deloitte”) as its auditor with effect from the accounting year ending 31 December 2018.
This follows a competitive audit tender process overseen by an Executive Steering Committee of GSK’s Audit & Risk Committee chaired by Judy Lewent, which culminated in a recommendation that was approved by the Board, the company said in its press release.
The current auditor PricewaterhouseCoopers LLP (“PwC”) will continue in their role and undertake the audit of the GSK until the year ending 31 December 2017, subject to reappointment by shareholders at the company’s 2017 Annual General Meeting. The appointment of Deloitte will be recommended to GSK’s shareholders for approval at company’s 2018 Annual General Meeting.
Judy Lewent, Chairman of the company’s Audit & Risk Committee, said: “I am pleased that having conducted a, thorough, open and transparent process, the Audit & Risk Committee has concluded the audit tender. We would like to thank PwC for their significant contribution as GSK’s auditor since the formation of GSK in 2001 and look forward to working with Deloitte in the future.”